ArticleResearch and practice in thrombosis and haemostasis2026
Avatrombopag in thrombopoietin receptor agonist-naïve patients with immune thrombocytopenia: real-world treatment patterns and clinical outcomes from the REAL-AVA 3.0 study.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Avatrombopag (AVA) is a thrombopoietin receptor agonist (TPO-RA) approved for patients with immune thrombocytopenia (ITP), but real-world data is limited in TPO-RA-naïve patients. Objectives: To describe treatment patterns and outcomes in TPO-RA-naïve adult patients with primary ITP treated with AVA. Methods: This retrospective chart review study included TPO-RA-naïve adults with primary ITP who initiated AVA on or after July 1, 2019, with ≥ 6 months of follow-up. Patients were followed from AVA initiation until the earliest of either last contact, death, or study end (January 20, 2025). Response was defined as achieving a platelet count (PC) ≥ 30, ≥ 50, or ≥ 100 × 10 Results: Among 200 patients, 84.0% initiated AVA with baseline PCs < 30 × 10 Conclusion: AVA is an effective treatment option for TPO-RA-naïve patients with ITP, demonstrating a high real-world rate of sustained PC response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.